

# CHANDRIKA PRUSTY

467/19 Shree Vihar, Patia, 751031 · +91-6371788074

[Chandrikaprusty91@gmail.com](mailto:Chandrikaprusty91@gmail.com)

Recent graduate of a top-tire university with a self-starter attitude and experience in genetics, biotechnology. Organized and dependable candidate successful at managing priorities with enthusiasm.

## EDUCATION

JUNE 2023

**MASTERS IN BIOTECHNOLOGY, TRIDENT ACADEMY OF CREATIVE TECHNOLOGY**

CGPA – 7.2

MAY 2020

**BACHELOR'S IN SCIENCE-HONORS ZOOLOGY, SRI JAYDEV COLLEGE OF ENGINEERING AND TECHNOLOGY**

CGPA – 7.5

JUNE 2017

**+2 SCIENCE, SRI JAYDEV COLLEGE OF EDUCATION AND TECHNOLOGY**

Percentage- 70%

## SKILLS

- DNA & RNA extraction
- PyMOL
- Schrodinger
- Python
- Gene Editing
- MS-Office/Adobe Creative cloud

## INTERNSHIPS

- Internship on “**Advanced Tools in Genetics and Biotechnology**” (Fish Genetics and Biotechnology Division ICAR- Central Institute of Freshwater Aquaculture)
  - Recent Advances in Aquaculture Biotechnology

- Molecular Mechanism of Endocrine Disruption and Biomarker identification
- Selective Breeding
- DNA Isolation
- Neuroendocrine Hormonal Regulation.
- cDNA synthesis and PCR
- Primer Designing

## **PROJECTS**

- **Extensive Immunoinformatic study for the prediction of novel peptide-based epitope vaccine with docking conformation against Serine-aspartate repeat-containing protein Staphylococcus Aureus bacteria- A computational Biology Approach-** (KIIT School of Biotechnology)
  - In the present study, immunoinformatic approaches were used to develop an effective vaccine against S.aureus infection.
  - With high cost demand and numerous limitations for developing life attenuated or inactivated vaccine preparation for infection against S.aureus. These peptides passed vaccine candidates could be relatively inexpensive and effective alternative option to fight Staphylococcal infection.
  - The potential B- and T- cell epitopes were mapped from antigens of serine-aspartate repeat containing cell wall adherence protein SdrD.
  - The developed multiepitope vaccine with a good immune response and wide population coverage and exhibiting high antigenicity, non-toxicity and non-allergenicity could be a potential candidate for clinical trials.